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The aim was to investigate whether bone tissue resorption in early RA is related to crepitus of the temporomandibular joint (TMJ)
and systemic levels of inﬂammatory mediators and markers and sex steroid hormones. Twentynine women and 18 men with
recently diagnosed RA were examined for TMJ bone erosions with computerized tomography and TMJ crepitus was assessed.
Blood samples were analyzed for glutamate, 5-HT, TNF, IL-1β, IL-6, VEGF, inﬂammatory markers, and estradiol, progesterone
and testosterone. The TMJ erosion score was positively correlated to glutamate, and TMJ crepitus where crepitus, glutamate and
ESR explained 40% of the variation in the bone erosion score. In the patients without crepitus, bone erosion score was positively
correlated to glutamate, which was not the case in the patients with crepitus. In conclusion, the results of this study show that TMJ
bone tissue resorption can be predicted by TMJ crepitus and glutamate in early RA.
1.Introduction
The main pathophysiology in rheumatoid arthritis (RA) is
found in the synovial tissues of peripheral joints as an exten-
sive inﬁltration of immunocompetent cells and high levels
of inﬂammatory mediators. One common outcome is that
inﬂammatory pannus tissue invades the cartilage and bone
surface and causes cartilage and bone tissue destruction.
This process results in joint crepitus, which is considered
to be a clinical sign of joint surface destruction in chronic
arthritides that is correlated to radiographic such as cortical
erosions in the temporomandibular joint (TMJ) and hand
joints [1, 2]. Crepitus in knee osteoarthritis has been found
to be the strongest clinical indicator of radiographic changes
in osteoarthritis (OA) [3]. However, another signiﬁcant part
of bone tissue resorption takes place within the subchondral
bone marrow as a response to the systemic inﬂammation
and mediators from the blood circulation [4]. Histologic
studiesofjointreplacementspecimenshaveshownthatbone
marrowresorptionswithinﬂammatorycellularinﬁltrates[5]
can be detected on MRI in 39%–75% of RA patients with
disease duration of less than 1 year [6]. This was further
shown in chronic RA patients subjected to joint replacement
surgery in ﬁnger joints comparing immunohistochemistry
with MRI [7].
We recently showed that TMJ bone tissue resorption
is associated with plasma levels of glutamate, especially in
patients with low-systemic inﬂammatory activity and low
levelofestradiolortestosterone[8].Themechanismsbehind
bone tissue resorption observed in the TMJ in early RA
may thus not be entirely related to systemic inﬂammation
but also to other factors such as hormones. The question
was therefore raised whether the glutamate-associated bone
tissue resorption observed in the TMJ in early RA is asso-
ciated with bone tissue destruction involving inﬂammatory
mediators such as serotonin (5-HT) and proinﬂammatory
cytokines or whether it is associated with noninﬂammatory
mechanisms.2 Mediators of Inﬂammation
Glutamate participates in normal bone turn over and
bone tissue remodeling [9, 10] The glutamate level has
been reported to be elevated in plasma [11] and synovial
tissues in RA [12], probably as a result of release from
activated thrombocytes [13, 14]. Continuous thrombocyte
activation in the synovial tissues might be accomplished by
proinﬂammatory cytokines such as tumor necrosis factor
(TNF) since thrombocytes express cytokine receptors [15].
Serotonin may be involved in bone tissue resorption and
the blood level of 5-HT has been related to erosions of TMJ
bone tissue in patients with RA [16, 17]. 5-HT, which is
mainly released from locally activated thrombocytes [18], is
present in the bone marrow [19, 20]a sw e l la st h es y n o v i a l
membrane [21], synovial ﬂuid [22], and blood plasma [23]
of patients with RA. How glutamate and 5-HT are related is
not known.
The sex steroid hormones estradiol, progesterone and
testosterone take part in bone metabolism. Estradiol is
known to suppress inﬂammation by inhibiting TNF [24, 25]
and to increase the expression of osteoprotegerin [26]a n d
thereby reduce bone resorption. The beneﬁcial eﬀects of
estradiol on bone and inﬂammation may be neutralized
and even antagonized by progesterone [27, 28]. Testosterone
enhances bone production [25, 28].
The aim of this study was to investigate whether TMJ
bone tissue resorption in early RA is related to gender or
proinﬂammatory mediators or markers or the sex steroid
hormones depending on whether there are clinical signs of
crepitus or not in the TMJ.
speciﬁc questions.
(1) Is bone resorption of the TMJ related to crepitus as
a clinical sign of articular cartilage and bone tissue
damage?
(2) Is bone resorption in patients with or without crepi-
tus related to glutamate, 5-HT, cytokines (TNF, IL-1,
IL-6, VEGF), CRP, ESR, RF, estradiol, progesterone
or testosterone?
(3) Are these relationships inﬂuenced by gender?
2.MaterialandMethods
2.1. Patients. Forty-seven patients, 29 females, and 18
males with RA were included in the study. Of these 28
(60%) were seropositive (Table 1). There was no statistically
signiﬁcant gender diﬀerence regarding the demographic
or background variables investigated. The patients were
consecutively invited to participate in the study after being
diagnosed at the Department of Rheumatology, Karolinska
University Hospital in Huddinge, Sweden. The inclusion
criteria were diagnosis of RA according to the criteria of the
American College of Rheumatology [29], age above 18, and
verbal consent. Exclusion criteria were current malignancies,
TMJ surgery or trauma within 2 years, recent intra-articular
glucocorticoid injection in the TMJ (within 1 month), and
conditions other than RA causing orofacial pain.
This project was approved by the regional ethical com-
mittee at Karolinska Institutet (03-204) and by the local
radiation committee at Karolinska University Hospital in
Huddinge (19/03).
2.2. Medication. Eighty-one percent of the patients were
on methotrexate treatment, which was initiated shortly
before they entered the study at the time of diagnosis.
Sixty-two percent used nonsteroidal anti-inﬂammatory drug
medication, 44% received glucocorticoids, either by oral
or intra-articular administration and 9% used salazopyrine
or received gold salt injection. Two female patients used
estradiol supplementation.
2.3. Clinical Protocol. The patients entered this study a
median (25th–75th percentile) of 23 (12–36) days after
diagnosis. They were examined clinically for joint crepitus,
blood samples were collected and radiographs were taken
during the same day. TMJ crepitus was assessed bilaterally
as absent (0), palpable (1), or audible (2) and thus with an
individual maximum score of 4.
The disease activity score comprising 28 joints (DAS28)
wasassessedattheDepartmentofRheumatology,Karolinska
University Hospital, Huddinge, Sweden, at the time of
diagnosis.
2.4. Radiographic Examination. Radiographic examination
of the TMJ region was performed with a cone-beam
computer tomograph (CBCT; NewTom QR DVT mod 9000,
Verona, Italy). The NewTom allowed a three-dimensional
digital volume representation of the TMJ region, enabling
sectionsofthisregioninanydesiredplane.Theexaminations
were performed with a standardized head position with the
TMJ located in the centre of the region of interest. The
maximum size of the region of interest was 130 × 130 ×
130mm and scanning time was 70 seconds. Reconstructions
were processed and analyzed by the NewTom software
(NewTom 3G). The CBCT sections were evaluated for
presence of erosions, that is, radiographic signs of bone
tissue resorption. Erosion was deﬁned as a local area with
decreased mineral density of the articular cortical bone
surface including or not including the adjacent subcortical
bone or as subcortical bone tissue resorption under intact
cortical bone. The erosions were assessed in 12 diﬀerent
regions of the condyle and temporal component of each
TMJ. The number of TMJ bone erosions was counted (0–24)
for each individual. The intraobserver consistency between
repeated readings of bone erosion was tested on the images
of 20 randomly selected joints from 10 of the patients. The
scoring system was tested in a blinded fashion by the same
radiologistattwooccasions2-3yearsapart.Onanindividual
level there was a total agreement in seven patients (70%) and
ad i ﬀerence by one score unit in the other three patients.
2.5. Blood Sampling and Laboratory Procedures. In order to
assess the inﬂammatory activity the inﬂammatory mark-
e r sE S R( n o r m a lr a n g e :♂ ≤ 70 years: ≤15mm/h and
♂ > 70 years: ≤20mm/h, ♀ ≤ 70 years: ≤20mm/h
and ♀ > 70 years: ≤28mm/h), CRP (normal range:
<3mg/L), RF (normal range: <15IU), thrombocyte particleMediators of Inﬂammation 3
Table 1: Demographic and background data for 47 patients with early rheumatoid arthritis.
Percentiles
Median 25th 75th Min Max Mean SD n %a b n
Gender M/F 18/29
Age years 62 53 67 25 79 58 14 47
Duration of general joint symptoms months 7 4 10 2.3 38 8 6 47
Duration of RA diagnosis days 23 12 36 3 115 27 20 47
Anti-cyclic citrullinated peptide IU/mL 30 0 453 0 2000 349 557 37 51
Rheumatoid factor IU/mL 23 0 173 0 910 130 221 47 51
C-reactive protein Mg/L 0 0 18 0 96 13 22 47 43
Erythrocyte sedimentation rate mm/h 22 17 32 6 85 28 18 47 49
Leukocyte particle count 109/L 7.5 5.6 8.7 4.3 15 7.8 2.7 39 54
T h r o m b o c y t ep a r t i c l ec o u n t 1 0 9/L 315 273 356 148 657 331 99 47 23
Disease activity score (DAS28) 0–10 6 5 6.5 4 7.8 6 1 44 100
Estradiol total pmol/L 62 34 82 15 1299 111 213 42
males pmol/L 65 62 85 48 140 77 25 17
females pmol/L 41 26 66 15 1299 133 275 25
Testosterone total nmol/L 1.2 0 10 0.0 22 5.0 6.1 42
males nmol/L 12 7.9 14 4.3 22 11 4.5 17
females nmol/L 0 0 0.9 0.0 3.5 0.6 0.8 25
Progesterone total nmol/L 0.4 0 1 0.0 2.1 0.6 0.6 42
males nmol/L 0.9 0.0 1.2 0.0 1.8 0.8 0.6 17
females nmol/L 0.0 0.0 0.7 0.0 2.1 0.4 0.6 25
% abn: percentage of observations with abnormal values when applicable, n: number of observations, M: males, F: tamales, IU: international units. The
following values ware considered abnormal: Anti-cyclic citrullinated peptide ≥25U/mL, rheumatoid tactor ≥20IU, C- reaclive protein ≥3mg/L, erythrocyte
sedimentation rate >24mm/h, leukocyte particle count > 8.8 × 109/L, and thrombocyte particle count ♂ > 348 × 109/La n d♀ > 387 × 109/L. The disease
activity score for 28 joints (DAS28) was assessed at the time for diagnosis.
count (TPC; normal range: ♂145–348 ∗109/L, ♀ 165–387
∗109/ L ) ,l e u k o c y t ep a r t i c l ec o u n t( L P C ;n o r m a lr a n g e :≤8.8
∗109/L), and anticyclic citrullinated peptide antibody titer
(anti-CCP) (normal range: <25U/mL) were analyzed in
serum. Levels of estradiol, progesterone and testosterone
were also determined in serum. All these analyses except
for erythrocyte sedimentation rate were performed with
standard procedures at the Department of Laboratory
Medicine (Clinical Chemistry and Immunology), Karolinska
University Hospital, Huddinge, Sweden. Determination of
the erythrocyte sedimentation rate was performed according
to the Westergren procedure.
Venous blood sampled in EDTA tubes was immediately
cooled and centrifuged (1500g for 10min at +4◦C) for
analysis of glutamate, TNF, IL-1β, and IL-6 in plasma.
Other venous blood samples were stored without additives
in room temperature for 1 hour to coagulate thereafter
centrifuged (1500g for 30min at +4◦C) for analyses of
5-HT serum levels. VEGF was analysed in lyzed whole
blood. After preparation, the supernatants without cells
were pipetted into polypropylene tubes except for serum
samples that were stored in polystyrene tubes in −80◦C until
analysis.
The concentrations of all investigated mediators were
determined by commercially available assays in our labora-
tory. Glutamate in plasma was analysed by the Amplex Red
Glutamic acid/glutamate oxidase assay (Amplex, Invitrogen,
Eugene, USA). This glutamate assay had a detection limit of
10μmol/L according to the manufacturer. No information
was given by the manufacturer about intra- and interassay
variation. The median (5th–95th percentile) plasma level of
glutamatein22healthyindividuals(meanage30years,range
20–54 years) was found to be 6.2 (0.3–18)μmol/L in our
laboratory.
TNF, IL-1β,and IL-6 in plasma were analysed with the
high-sensitivity human cytokine Lincoplex kit for simulta-
neous multianalyte detection with Luminex technology and
instrumentation (Lincoplex kit, Linco Research, St Charles,
USA). The assay minimum detection concentration is 0.05
(TNF),0.06(IL-1β),and0.10(IL-6)pg/mL,respectively.The
intra-assay coeﬃcients of variation are 3.5% (TNF), 3.1%
(IL-1β), and 3.5% (IL-6) and the inter-assay coeﬃcient are
3.8% (TNF), 2.2% (IL-1β), and 4.5% (IL-6). The median
(5th–95th percentile) levels of TNF (n = 30), IL-1β (n =
30) and IL-6 (n = 30) in a healthy control group have
been reported to be 3.3 (1.2–7.8), 0.33 (0.0–2.1), and
187 (0.0−60)pg/mL, respectively [30]. The healthy group
referenced comprised 48 subjects (23 men and 25 women;
mean age 53 years, range 39–69 years).
VEGF was analysed by a commercially available enzyme-
linked immunoassay kit (Quantikine Human Immunoas-
says, R&D Inc, Minneapolis, USA) in lysed whole blood. The
median (range) VEGF level in normal lysed whole blood is
298 (92 to 554)pg/mL [31].4 Mediators of Inﬂammation
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Figure 1: Scatter plots showing (a) the relationship between plasma level of glutamate and temporomandibular joint (TMJ) bone erosion
score in the patients with crepitus (rs =− 0.35, n = 12, P = .253) and (b) in the patients with no crepitus (rs = 0.45, n = 35, P = .007). •:
crepitus, ◦: no crepitus.
5-HT was analyzed by a commercially available com-
petitive enzyme immunoassay kit (EIA-kit. No 0642,
Immunotech International, Marseille, France). The kit has a
detection limit and sensitivity of 0.5nmol/L. The intra-assay
coeﬃcient of variation is less than 9.4% and the interassay
coeﬃcient of variation is less than 9.9%, according to the
manufacturer. Normal serum 5-HT has a median (25th–
75th percentile) of 602 (339−957)nmol/L, for males 626
(271−1819; n = 19, age = 35 (27−41) and for females 882
(437−1666)nmol/L (n = 35, age = 39 (30−51) according to
our data. The levels are not correlated to age (rs =− 0,112,
n = 52, P = .427).
Blood samples were also drawn to determine the serum
levels of estradiol, progesterone and testosterone, according
to standard procedures at the Department of Laboratory
Medicine (Clinical Chemistry and Immunology), Karolinska
University Hospital, Huddinge, Sweden. The normal refer-
ence range according to the laboratory for estradiol levels
in fertile women was 100–1500pmol/L, in postmenopausal
women <50pmol/L and in men 50–150pmol/L. The nor-
mal reference intervall for progesterone levels in fertile
women was at follicular phase <4.8nmol/L and luteal phase
>17nmol/L and in postmenopausal women <3.0nmol/L. In
men the normal progesterone interval was <3.0nmol/L. The
range for testosterone levels in women was <2.7nmol/L and
in men 6–30nmol/L.
2.6. Statistics. Median, min, max, and the 25th and 75th
p e r c e n t i l e sa sw e l la sm e a na n ds t a n d a r dd e v i a t i o nw e r e
used for descriptive statistics. Correlations between the
variables were tested in all patients as well as prespeciﬁed
subgroups according to gender and TMJ crepitus by the
Spearman rank correlation coeﬃcient (rs) .I no r d e rt os e l e c t
the strongest independent predictors to TMJ bone erosion
score a stepwise linear multiple regression analysis was
performed. Interaction analysis was performed by including
an interaction term in addition to the main eﬀects in
the multiple linear regression model. The signiﬁcance of
diﬀerences according to gender and crepitus was tested with
the Mann-Whitney U-test. A probability level of less than.05
was considered signiﬁcant.
3. Results
The demographic and background variables are shown in
Table 1. The levels of the inﬂammatory mediators as well as
the bone erosion and crepitus scores are shown in Table 2.
Bone erosion score was positively correlated to glutamate
(rs = 0.30, P = .042) and TMJ crepitus (rs = 0.38, P = .008),
while glutamate and TMJ crepitus were not signiﬁcantly
related (rs =− 0.08, P = .590).
Multiple stepwise regression showed that the indepen-
dent variables TMJ crepitus (P<. 001), glutamate (P =
.005), and ESR (P = .010) were positively related to and
explained 41% of the variation in the dependent variable
TMJ bone erosion score (P<. 001). Gender, 5-HT, TNF,
IL-1, IL-6, VEGF, estradiol, progesterone, testosterone, RF,
CRP, and ESR were also included into the stepwise regression
but did not signiﬁcantly add to the ability of the model to
predict erosion score. In the patients without TMJ crepitus,
bone erosion score was positively correlated to glutamate
(rs = 0.45, n = 35, P = .007; Figure 1). The corresponding
correlation in the patients with crepitus was negative but
did not reach statistical signiﬁcance (rs =− 0.35, n = 12,
P = .264; Figure 1). Interaction analysis with multiple linear
regression showed that there was a diﬀerent relation (P =
.050) between bone erosion score and glutamate level in the
patients without crepitus compared to those with crepitus.
Theboneerosionscorewaspositivelycorrelatedtooneof
theinvestigatedmediatorsofinﬂammation,5-HT(rs = 0.54,
n = 16, P = .030; Figure 2), in males. The corresponding
correlation in the females was negative but did not reachMediators of Inﬂammation 5
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Figure 2: Scatter plots showing (a) the relationship between serum level of serotonin and temporomandibular joint (TMJ) bone erosion
score in the male patients (rs = 0.54, n = 16, P = .031) and (b) in the female patients (rs =− 0.34, n = 27, P = .080). •: males, ◦: females.
Table 2: Erosion score as well as level of TMJ erosion score and inﬂammatory mediators in blood samples from 47 patients with early
rheumatoid arthritis.
Percentile
Median 25th 75th Min Max Mean SD n %abn
Erosion score 0–24 2.0 00 3.8 0 9 2.4 2.3 47 72
TMJ crepitus 0–4 0 0 0.8 0 4 0.3 0.7 47 26
Blood levels
Plasma
Glutamate μmol/L 3.4 1.0 7.2 0.1 10.2 4.1 3.2 47
T u m o rn e c r o s i sf a c t o r Pg/mL 9 7.5 14 4.0 107 14 16 47 68
Interleukin-1β pg/mL 3.3 1.1 7.7 0.5 46 5.2 7.1 47 64
Interleukin-6 pg/mL 27 14 36 2.8 200 32 32 47 36
Serum
Serotonin nmol/L 610 358 958 16.3 1818 667 395 43
Whole blood
Vascular endothelial growth factor Pg/mL 143 99 186 46 1027 179 170 36 28
n:n u m b e ro fo b s e r v a t i o n s ,% abn: % of patients with values outside the 5th–95th percentile range according to the reference values (see Section 2).
statistical signiﬁcance (rs =− 0.34, n = 27, P = .080;
Figure 2).Interactionanalysiswithmultiplelinearregression
showed a signiﬁcant (P = .014) interaction between gender
and 5-HT. This implies a signiﬁcant diﬀerence in relation
between bone erosion and 5-HT in males compared to
females.
4. Discussion
This study shows that glutamate is related to articular bone
tissue resorption in the TMJ of patients with early RA
without joint crepitus and that the presence bone resorption
can be predicted by presence of joint crepitus and plasma
level of glutamate.
The crepitus in this study is mainly palpable (21%) and
infrequently audible (2%), which indicates a lower degree
of tissue destruction in agreement with the short disease
duration. The frequency of crepitus was lower in this study
than in a previous study where 75% of both male and
female RA patients were reported to have crepitus [32].
However, the majority of these patients had disease duration
of more than 5 years. Another study reported a weak but
statistically signiﬁcant relationship between crepitus and
radiologic changes of the TMJ in RA patients, where 80%
of joints with crepitus showed evidence of articular bone
erosion while only 47% of joints with radiologic erosion had
crepitus [2]. This latter ﬁnding is in agreement with ours and
indicates that articular bone erosions develop with diﬀerent
mechanisms. The regression model also included ESR as a
predictor of bone resorption when the other variables were
considered. ESR was not signiﬁcantly correlated to the bone
erosion score in the non-parametric univariate analysis and6 Mediators of Inﬂammation
this relationship should therefore be interpreted with great
caution. However, such a relation can be expected for ero-
sionsofsystemicinﬂammatorynatureandstrongassociation
between serial measurements of ESR and radiographic joint
destruction has been found [33].
The relationship between bone tissue resorption and
serum level of 5-HT seems to be positive and speciﬁc
for men since there was a signiﬁcant gender diﬀerence
regarding this relationship. Plasma and serum levels of 5-
HT have been reported to be associated with progression
of TMJ bone resorption during a 25–46 month interval
in patients with established RA [17], indicating a systemic
inﬂuenceby5-HTonlocalbonetissueresorption.5-HTmay
modulate osteoblast bone formation via the 5-HT2B receptor
[11, 34, 35] and the osteoclast diﬀerentiation through its
transporter 5-HTT [19]. The exact nature of the 5-HT
contribution to bone tissue resorption and the inﬂuence of
gender is, however, still unclear. In this study, the observed
bone tissue resorption cannot be considered as normal
remodelingduetothecombinationwithactiveRA.However,
5-HT may play an important role for articular bone tissue
remodeling in both healthy individuals and in patients with
RA since osteocytes and osteoblasts express receptors for 5-
HT and 5-HTT [36]. A longitudinal study of mainly female
patients withchronicRAremarkablyshowedthatlow-serum
levels of 5-HT were associated with progression of erosions,
while high levels were associated with regression [17].
Whether glutamate or 5-HT is associated with continuing
bone tissue resorption in the early stage of RA is not yet
known.
In this study, no dietary precautions like fasting were
taken before blood sampling and quantiﬁcation of 5-HT
and glutamate. The plasma level of glutamate found in
this study is lower than that reported from a previous
study of RA patients [8] as well as in a sample of healthy
individuals investigated in our clinic. A signiﬁcantly higher
nonfasting level of glutamate was found in the RA patients in
comparisonwithhealthyindividuals[8].Thispreviousstudy
deviates from ours regarding age and disease duration of the
patients. However, since no relation was observed between
glutamate level and age nor disease duration in our patient
sample [11], the discrepancies between the studies may be of
methodological nature.
The patients included had a recently diagnosed RA and
most of them were examined for this study within less than
one month after diagnosis and about 6 months after their
report of debut of symptoms. Most patients commenced
anti-inﬂammatory medication shortly after diagnosis and
before the start of this investigation. An inﬂuence of the
medication on the levels of inﬂammatory markers and
mediators is likely but the inﬂuence of the medication on the
radiographic signs of bone tissue resorption can be expected
to be minor or even insigniﬁcant.
Inconclusion,theresultsofthisstudyshowthatpresence
of bone tissue resorption of the TMJ can be predicted by
presence of a combination of joint crepitus and elevated
plasma level of glutamate in early RA. The relation between
glutamate and TMJ bone tissue resorption is diﬀerent in
patients with or without crepitus indicating that glutamate
has a particular role in joints without surface destruction.
The results also show that bone tissue resorption at this early
stage is related to the inﬂammatory mediator 5-HT in men
but not in women.
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